BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TrovaGene, Inc. Shares Focus of New Molecular Diagnostics Analysis


9/7/2012 11:20:28 AM

SAN DIEGO – Trovagene, Inc., a developer of transrenal molecular diagnostics, was placed in lofty company with Abbott Diagnostics and Rosetta Genomics in the increasingly important molecular diagnostics sector. Mel Daris, a former mutual fund industry trader from Boston who currently trades independently, singled out the three companies in a Seeking Alpha report on the medical community’s expanding interest in molecular diagnostic testing.

“With advances in testing procedures, especially transrenal DNA diagnostics, patients can expect much less stress and pain when undergoing testing procedures,” the September 4 report said.

“Not only will this enhance a patient’s health and reduce risk of fatality, this also increases profits for companies providing diagnostic services.”

Daris said Abbott Diagnostics is controlled by Abbott Laboratories, and provides testing services and equipment to a variety of medical outlets, and Rosetta has developed tests for specific types of lung cancer.

On Trovagene (NASDAQ: TROV), the report said: “Over the past year, Trovagene has shown it’s a fierce competitor in the transrenal molecular diagnostics area. In addition to obtaining a license to study SF3B1 markers, the company also acquired MultiGEN Diagnostics clinical laboratory...for expansion purposes. The company also has plans to collaborate with The University of Texas MD Anderson Cancer Center to develop testing procedures to help diagnose those with pancreatic cancer.”

Daris concluded that investors should pay particular attention to transrenal DNA testing “as this form of molecular diagnostics could become the new standard in testing for disease... (and) from a long-term investment perspective, molecular diagnostics should provide strong and steady returns.”

The full Seeking Alpha report may be viewed at: http://seekingalpha.com/article/844971-3-stocks-to-consider-in-molecular-diagnostics

The report follows closely on Trovagene’s announcement that it has received a milestone payment from Ipsogen S.A., a subsidiary of the QIAGEN group, resulting from a co-exclusive license agreement to manufacture and sell diagnostic kits for the detection of nucleophosmin protein (NPM1) mutations in patients with acute myeloid leukemia (AML).

“Trovagene is continuing to expand its commercial activity through its CLIA lab offerings and through external licensing opportunities,” said Antonius Schuh, chief executive officer of Trovagene.

The full announcement may be viewed at: http://www.trovagene.com/Press-Room/Latest-News/Trovagene,-Inc-,-Achieves-Intellectual-Property-Mi.aspx

Trovagene, headquartered in San Diego, is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. As a non-invasive and abundant sample, urine may overcome many of the cost and collection challenges presented by biopsy, as well as the volume limitations of blood.

Contact: Alex Michelini The Promotion Factory michelinialex@aol.com 5 E. 19th Street New York, NY 10003 T. 212-217-9065 F. 212-217-9075



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES